| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) EA Eisenhauer, P Therasse, J Bogaerts, LH Schwartz, D Sargent, R Ford, ... European journal of cancer 45 (2), 228-247, 2009 | 27918 | 2009 |
| New guidelines to evaluate the response to treatment in solid tumors P Therasse, SG Arbuck, EA Eisenhauer, J Wanders, RS Kaplan, ... Journal of the national cancer institute 92 (3), 205-216, 2000 | 18849 | 2000 |
| Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial GD Demetri, AT van Oosterom, CR Garrett, ME Blackstein, MH Shah, ... The Lancet 368 (9544), 1329-1338, 2006 | 3173 | 2006 |
| Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation H Gelderblom, J Verweij, K Nooter, A Sparreboom European journal of cancer 37 (13), 1590-1598, 2001 | 2117 | 2001 |
| Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial J Verweij, PG Casali, J Zalcberg, A LeCesne, P Reichardt, JY Blay, ... The Lancet 364 (9440), 1127-1134, 2004 | 2094 | 2004 |
| Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study AT van Oosterom, I Judson, J Verweij, S Stroobants, ED di Paola, ... The Lancet 358 (9291), 1421-1423, 2001 | 1588 | 2001 |
| KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours M Debiec-Rychter, R Sciot, A Le Cesne, M Schlemmer, P Hohenberger, ... European journal of cancer 42 (8), 1093-1103, 2006 | 1064 | 2006 |
| Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial I Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, JY Blay, ... The lancet oncology 15 (4), 415-423, 2014 | 997 | 2014 |
| Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) RHJ Mathijssen, RJ van Alphen, J Verweij, WJ Loos, K Nooter, G Stoter, ... Clinical cancer research 7 (8), 2182-2194, 2001 | 923 | 2001 |
| Pharmacological effects of formulation vehicles: implications for cancer chemotherapy AJ Ten Tije, J Verweij, WJ Loos, A Sparreboom Clinical pharmacokinetics 42, 665-685, 2003 | 801 | 2003 |
| Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors JC Bendell, J Rodon, HA Burris, M De Jonge, J Verweij, D Birle, ... J Clin Oncol 30 (3), 282-290, 2012 | 774 | 2012 |
| Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas I Ray-Coquard, C Cropet, M Van Glabbeke, C Sebban, A Le Cesne, ... Cancer research 69 (13), 5383-5391, 2009 | 770 | 2009 |
| Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for … S Sleijfer, I Ray-Coquard, Z Papai, A Le Cesne, M Scurr, P Schöffski, ... Journal of clinical oncology 27 (19), 3126-3132, 2009 | 769 | 2009 |
| Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study RD Issels, LH Lindner, J Verweij, P Wust, P Reichardt, BC Schem, ... The lancet oncology 11 (6), 561-570, 2010 | 765 | 2010 |
| Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia PJ Valk, RG Verhaak, MA Beijen, CA Erpelinck N Engl J Med 350 (16), 1617-28, 2004 | 648* | 2004 |
| Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a … M Van Glabbeke, AT Van Oosterom, JW Oosterhuis, H Mouridsen, ... Journal of Clinical Oncology 17 (1), 150-157, 1999 | 635 | 1999 |
| Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for … A Santoro, T Tursz, H Mouridsen, J Verweij, W Steward, R Somers, ... Journal of Clinical Oncology 13 (7), 1537-1545, 1995 | 631 | 1995 |
| Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II … M Debiec-Rychter, H Dumez, I Judson, B Wasag, J Verweij, M Brown, ... European journal of cancer 40 (5), 689-695, 2004 | 584 | 2004 |
| Effects of St. John's wort on irinotecan metabolism RHJ Mathijssen, J Verweij, P De Bruijn, WJ Loos, A Sparreboom Journal of the National Cancer Institute 94 (16), 1247-1249, 2002 | 581 | 2002 |
| Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European … A Ardizzoni, H Hansen, P Dombernowsky, T Gamucci, S Kaplan, ... Journal of clinical oncology 15 (5), 2090-2096, 1997 | 581 | 1997 |
